Desentum Oy

Teknologian Tutkimuskeskus Vtt

Teknologian Tutkimuskeskus Vtt Oy

Merja Niemi

Kristiina Takkinen

Juha Rouvinen

Marja-Leena Laukkanen

Hans Söderlund

Sirpa Jylhä

Janne Jänis

Hans Soederlund

Sirpa Jylhae

Soili Mäkinen-Kiljunen

Tari Haahtela

Jaana Haka

Heidi Holkeri

Sirpa Jylha

Soili Maekinen-Kiljunen

Hans Soderlund

Janne Janis

The present invention relates to specific modified Equ c 1 polypeptides and to the use of such polypeptides as hypoallergens for desensitizing against horse allergy. Particularly, the present invention provides a recombinant hypoallergenic Equ c 1 polypeptide comprising at least two amino acid modifications compared to a corresponding wild type Equ c 1 allergen, wherein the recombinant hypoallergenic polypeptide activates release of histamine from basophils to a degree less than the wild type allergen.

Recombinant hypoallergenic Equ c 1 polypeptides for use in the immunotherapy of horse allergy

The present invention provides mutant polypeptides useful as hypoallergens. More specifically the present invention provides mutant Bet v 1 proteins and the use of such polypeptides as hypoallergens for desensitizing against birch pollen allergies. Furthermore, the invention provides vaccine formulations comprising such polypeptides; the use of such formulations; and to methods of vaccination against birch pollen allergy.

Hypoallergen

The present invention relates to human IgE antibodies and derivatives thereof, which bind non-continuous planar allergenic epitope, such as in &#x3b2;-lactoglobulin, with high affinity and specificity. The present invention also relates to processes for making and engineering such allergen binding monoclonal antibodies and to methods for using these antibodies and derivatives thereof in the field of immunodiagnostics and immunotherapy.

Allergen-binding IgE monoclonal antibodies and method for preparing hypoallergens

The present invention is related to field of allergic (hypersensitivity) diseases and provides a method for producing modified allergenic polypeptides for use in immunotherapies. In the method of the invention, said allergenic polypeptides are modified so that they are not capable to form transient dimers. The invention also provides modified &#x3b2;-lactoglobulins for use in immunotherapy of milk allergy.

Modified beta-lactoglobulins for immunotherapy of milk allergy

Growing community of inventors

Joensuu, Finland

Merja Niemi